Barclays raised the firm’s price target on Replimune Group to $17 from $13 and keeps an Overweight rating on the shares. The company reported positive topline data for RP1 plus nivolumab in advanced melanoma by central review which was consistent with prior data presented by investigator assessment, the analyst tells investors in a research note. The firm says the data continues to support potential accelerated approval.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune Group’s IGNYTE Trial Shows Promising Melanoma Outcomes
- Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
- Replimune Group presents positive data from RP1 and RP2 programs at ASCO
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue